Stereotactic Body Radiotherapy for Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2011
End Date:June 2018
Contact:Jaymeson Stroud, MD
Email:jaymeson.stroud@mercy.net
Phone:314-251-6844

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer

This study will evaluate the local control rate as well as acute and late toxicity rates of
stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.

This is a single site, non-randomized, prospective, phase IV trial of patients with
organ-confined prostate cancer. Data collected will include patient demographics, pathology
data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal
tissues,tumor recurrence data, and acute and late toxicities. Follow up data will be
collected during the patient's standard office visits. The anticipated duration of this
study is 5 years.

Inclusion Criteria:

- Patient age >= 18 years

- Zubrod performance status of 0-3

- T1-3 N0 M0 adenocarcinoma of the prostate

- Prostate volume ≤ 100 cc

- Signed study-specific consent form

Exclusion Criteria

- Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)

- Prostate volume > 100 cc

- Nodal involvement

- Metastatic disease

- Prior pelvic radiotherapy except as part of combination therapy for prostate cancer

- History of scleroderma

- Patients with psychiatric or addictive disorder that would preclude obtaining
informed consent
We found this trial at
1
site
Mercy Hospital St. Louis
St. Louis, Missouri 63141
?
mi
from
St. Louis, MO
Click here to add this to my saved trials